JENSCARE-B Multi-product portfolio LuX-Valve Plus TRINITY research, JensClip and Ken-Valve clinical results will be released at TCT 2025 in the United States, with remarkable outcomes
JENSCARE-B released multiple clinical research results of its products at the TCT 2025 conference in the United States, including the TRINITY trial results of LuX-Valve Plus, and the clinical effects of JensClip and Ken-Valve. These studies involved transcatheter tricuspid valve replacement, the safety and efficacy of the transjugular approach, and the application effects of transcatheter aortic valve replacement, demonstrating significant clinical outcomes
According to the announcement from JENSCARE-B (09877), recent results from the global multicenter clinical trial ("TRINITY") of the LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) system, including 6-month clinical follow-up results and evidence of efficiency and safety via the transjugular approach, as well as the one-year follow-up results and application effects of challenging cases for the JensClip transcatheter mitral valve repair (TMVr) system, and the one-year follow-up results and application effects of challenging cases for the Ken-Valve transcatheter aortic valve replacement (TAVR) system, will be presented at the TCT 2025 Transcatheter Cardiovascular Therapeutics Conference held in San Francisco, USA
